Beginning Cash: The amount of cash reported by the company on its previous statement.
Viking Therapeutics, Inc. (VKTX) had Beginning Cash of $26.68M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-157.66M |
|
-- |
|
-- |
|
$164.74M |
|
$-164.74M |
|
$7.08M |
|
$-157.66M |
|
$-157.70M |
|
$-157.66M |
|
$-157.66M |
|
$-157.66M |
|
$-157.70M |
|
$-164.74M |
|
$-166.38M |
|
112.67M |
|
112.67M |
|
$-1.39 |
|
$-1.39 |
|
| Balance Sheet Financials | |
$715.60M |
|
-- |
|
$0.13M |
|
$715.73M |
|
$76.67M |
|
-- |
|
-- |
|
$76.67M |
|
$639.06M |
|
$639.06M |
|
$639.06M |
|
114.79M |
|
| Cash Flow Statement Financials | |
$-278.69M |
|
$341.39M |
|
$76.44M |
|
|
Beginning Cash |
$26.68M |
$165.81M |
|
$139.13M |
|
$40.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-278.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.67% |
|
-24.67% |
|
-22.03% |
|
-24.67% |
|
$5.57 |
|
$-2.47 |
|
$-2.47 |
|